Editorial
We need innovations. Innovations keep both clinicians and patients excited about the promise of difference a new technique or devices can make. But innovations cost: Who should pay the costs is a subject of perennial debates. Who should deliver such innovations to patients with chronic wounds since these require interest, skills, and expertise to monitor and manage?
The management of chronic wounds is based on the concept of standardized care, which, in turn, is dependent on an accurate diagnosis and mainstay management. Given the issues of persistent inflammation and, in some situations, infection as well as underlying comorbidities, chronic wound healing is variable, and frequently recurrent. We seek and often find helpful devices that are aimed to deliver healing directly by improving wound healing times and/or via well-described secondary outcomes. But these devices come with a "cost". What determines the utilitarian value of such innovations-cost, ease of use, success? These parameters must be taken together with the cost of accessing the innovation either through purchase or leasing. It is worth taking a compartmental view of this situation.
Consider the stages in device or technique development:
Step 1: Birth of a concept and early development
Step 2: Proof of concept
Step 3: Validity, safety
Step 4: Preliminary trial runs
Step 5: Develop robust device to determine efficacy
Step 6: Determine evidence of safety, clinical efficacy, and cost-effectiveness
Step 7: Which cohorts' needs does the device best suit
Step 8: Large-scale everyday use Commonly, Steps 1 to 5 are funded by the innovators themselves or in collaboration with a grant funder/industry. Steps 6 and 7 are relatively giant steps needing larger cohorts, meticulous study design, and careful data analysis-these steps demand bigger resources. Once a device successfully emerges from these, it will need even greater resources, because to be employed in regular use calls for a wide range of skill, training, and education in other commitment to regular funding. Presently, it is regularly reported that the increased cost of health care per se may in large part be attributed to technology use and an increasing demand for care for the elderly. Since chronic wounds mainly concern the elderly, would it be beneficial for wound care to be delivered by trained clinicians "assistants"? Such clinician assistants would be interested in using new technology and willing to be trained in the basic skill of wound diagnosis. Adequately trained, clinician assistants would deliver wound care at homes and report electronically to local clinician/tissue viability experts to whom the patient was initially referred. The mobility of this new breed of expert and their interest in using the mobile phone and the Internet will permit busier and higher trained clinicians to attend to patients' wounds from a distance. In remote parts of countries this can only benefit the delivery of care, thereby translating the real value of innovations. Perhaps the training of such clinician assistants could be part of a partnership between industry and major health care providers? 
